Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 13:10:13-22.
doi: 10.1016/j.ctro.2018.02.005. eCollection 2018 Mar.

Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives

A Schernberg  1 , E Rivin Del Campo  1 , B Rousseau  2 , O Matzinger  3 , M Loi  4 , P Maingon  5   6 , F Huguet  1   2   3   4   5   6
Affiliations
Review

Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives

A Schernberg et al. Clin Transl Radiat Oncol. .

Abstract

An estimated 990,000 new cases of gastric cancer are diagnosed worldwide each year. Surgical excision, the only chance for prolonged survival, is feasible in about 20% of cases. Even after surgery, the median survival is limited to 12 to 20 months due to the frequency of locoregional and/or metastatic recurrences. This led to clinical trials associating surgery with neoadjuvant or adjuvant treatments to improve tumor control and patient survival. The most studied modalities are perioperative chemotherapy and adjuvant chemoradiotherapy. To date, evidence has shown a survival benefit for postoperative chemoradiotherapy and for perioperative chemotherapy. Phase III trials are ongoing to compare these two modalities. The aim of this review is to synthesize current knowledge about adjuvant chemoradiotherapy in the management of gastric adenocarcinoma, and to consider its prospects by integrating modern radiotherapy techniques.

Keywords: 5FU, 5-fluorouracil; 5FU-LV, 5-fluorouracil leucovorin; Adenocarcinoma; Adjuvant therapy; CRT, chemoradiotherapy; CT, chemotherapy; Chemoradiotherapy; DCF, Doxorubicin Cisplatin 5-fluorouracil; ECF, Epirubicin Cisplatin 5-fluorouracil; ECX, Epirubicin Cisplatin Capecitabin; FOLFOX, 5-fluorouracil oxaliplatin; FUFOL, bolus 5-fluorouracil followed by leucovorin over 15 minutes; Gastric cancer; IMRT; IMRT, intensity modulated radiation therapy; LV, leucovorin; RT, radiation therapy; XELOX, capecitabin oxaliplatine.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Gastric lymph nodes groups localization, according to the Japanese gastric cancer treatment guidelines.
See this image and copyright information in PMC

References

    1. Karimi P., Islami F., Anandasabapathy S., Freedman N.D., Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23(5):700–713. - PMC - PubMed
    1. Forman D., Burley V.J. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol. 2006;20(4):633–649. - PubMed
    1. Moertel C.G., Childs D.S., O’Fallon J.R., Holbrook M.A., Schutt A.J., Reitemeier R.J. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J Clin Oncol. 1984;2(11):1249–1254. - PubMed
    1. Dent D.M., Werner I.D., Novis B., Cheverton P., Brice P. Prospective randomized trial of combined oncological therapy for gastric carcinoma. Cancer. 1979;44(2):385–391. - PubMed
    1. Allum W.H., Hallissey M.T., Ward L.C., Hockey M.S. A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. British Stomach Cancer Group. Br J Cancer. 1989;60(5):739–744. - PMC - PubMed

LinkOut - more resources